CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to report resultson November 13 (estimated) for the period ending January 1 0001
LSEG's mean analyst estimate for CNS Pharmaceuticals Inc is for a loss of 10 cents per share.
The one available analyst rating on the shares is "buy".
The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".
Wall Street's median 12-month price target for CNS Pharmaceuticals Inc is $0.50, above its last closing price of $0.12.
This summary was machine generated November 11 at 15:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments